



Prenatal /Preconception Genetic Testing to Determine Carrier State of a Parent or Prospective Parent

Last Revision/Review Date: March 20, 2019

P&P # C.6.18

Policy

The Medical Management Department reviews referral requests for prior authorization of prenatal genetic testing of parents or prospective parents for determination of carrier states for inheritable diseases or disorders.

This Medical Policy does not constitute medical advice. When deciding coverage, the enrollee's specific plan document must be referenced. The terms of an enrollee's plan document (Certificate of Coverage (COC) or Summary Plan Description (SPD)) may differ from this Medical Policy. In the event of a conflict, the enrollee's specific benefit plan document supersedes this Medical Policy. All reviewers must first identify enrollee eligibility, any federal or state regulatory requirements, and the plan benefit coverage prior to use of this Medical Policy. Other Policies and Coverage Determination Guidelines may apply. Quartz reserves the right, in its sole discretion, to modify its Policies and Guidelines as necessary.

Procedure

A. Documentation Required:

1. Name of the test to be performed
2. Characteristics of the requested genetic test
3. Potential impact of genetic test on patient's medical decision making
4. Patient's risk of having the suspected mutation
5. Clinical records of genetic counseling
6. Genetic counseling must be performed by a qualified, appropriately trained practitioner with **ONE** of the following backgrounds:
 - a. Board certified/Board eligible (BC/BE) genetics counselor;
 - b. BC/BE medical geneticist;
 - c. Genetic nurse credentialed as either a genetic clinical nurse or advanced practice nurse in genetics;
 - d. Physician specialist or advanced practice professional in obstetrics, gynecology or reproductive medicine with experience or documented training and expertise in prenatal genetics.
 - e. The person providing the counseling cannot be employed by a commercial genetic testing laboratory except those employed by/contracted by a laboratory that is part of an integrated health system which routinely delivers health care services beyond just the laboratory test itself.
7. A general description of each specific disease or condition to be tested
8. The ordering providers statement of how the patient's medical treatment plan will be directed by the requested genetic testing whether testing results are positive or negative

B. General Criteria for Medical Necessity: (Used if specific genetic test is not listed in Section C) Prenatal /Preconception Genetic Testing of Inherited Disorders is medically necessary when **ALL** the following criteria are met:

1. The parents or prospective parents are at high risk of a specific genetic disorder with an autosomal recessive pattern of inheritance with an allele frequency of at least 1:100;
AND
2. A specific mutation, or set of mutations, has been established in the scientific literature to be reliably associated with the disease, including both a clear association between the genotype and phenotype as well as a high allele detection rate; **AND**
3. The genetic disorder is associated with a potentially severe disability or has a lethal natural history;
AND
4. Testing is accompanied by genetic counseling performed by a qualified, appropriately trained practitioner (see Definitions section above).

C. Medical Necessity Criteria for Specific Genetic Tests:

Prenatal /Preconception Genetic Testing of the following identified inherited disorders are considered medically necessary when the following criteria are met:

1. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene mutation:

American College of Medical Genetics (ACMG) 23-mutation panel for CFTR is medically necessary for **ANY** of the following indications:

- a. Couples seeking prenatal care; **OR**
- b. Couples who are planning a pregnancy; **OR**
- c. Persons with a family history of cystic fibrosis; **OR**
- d. Persons with a first degree relative identified as a cystic fibrosis carrier; **OR**
- e. Reproductive partners of persons with cystic fibrosis.

Note: CFTR full gene sequencing will only be covered if the patient's partner is positive for a deleterious CFTR mutation and the patient has a family history of CF with a negative 23-mutation CFTR panel.

2. Ashkenazi Jewish (see DEFINITIONS) descent carrier screening:

Screening those of Ashkenazi Jewish descent is medically necessary for **ANY** of the following disorders as specified by the American College of Medical Genetics (ACMG) and the American College of Obstetricians and Gynecologists (ACOG):

- a. Cystic Fibrosis
- b. Familial Dysautonomia
- c. Canavan Disease
- d. Tay-Sachs Disease

NOTE: Screening for disorders other than the four listed above is experimental or not medically necessary unless the prospective parent has other risk factors meeting the general criteria in Section B.

3. Fragile-X:

Screening for Fragile-X gene mutation is medically necessary when **BOTH** of the following criteria are met:

- a. Individuals planning a pregnancy who have **EITHER** of the following:
 - i. A family history of Fragile X related disorders, **OR**
 - ii. A family history of intellectual disability suggestive of Fragile X syndrome;
- b. The results of the test will affect the patient's reproductive decisions.

4. Huntington Disease

Screening for CAG repeat length mutation in the HTT gene for Huntington disease is considered medically necessary in asymptomatic patients when **BOTH** of the following criteria are met:

- a. Individuals planning a pregnancy who have **ONE** of the following:
 - ii. A first-degree blood relative - parent or sibling - with documented Huntington disease, **OR**
 - iii. Have a second-degree blood relative – grandparent, aunt or uncle - with documented Huntington disease and the first-degree blood relative status is unknown.
- b. The results of the test will affect the patient's reproductive decisions.

5. Marfan syndrome

Screening for a FBN1 gene mutation by sequence analysis followed by deletion and duplication analysis testing if negative for Marfan syndrome is considered medically necessary when **BOTH** of the following criteria are met:

- a. Individuals planning a pregnancy who have **ONE** of the following:
 - i. Suspected, but not confirmed, Marfan syndrome in patients with BOTH of the following:
 - 1. Absence of a confirmed family history of Marfan syndrome, **AND**
 - 2. Diagnosis of ectopia lentis with any aortic dilation or significant aortic dilation or dissection; **OR**
 - ii. Asymptomatic individual with a first-degree blood relative with Marfan Syndrome and a known genetic mutation (test for known familial mutation);
- b. The results of the test will affect the patient's reproductive decisions.

6. Spinal Muscular Atrophy (SMA):

Screening for spinal muscle atrophy by testing for deletions in *SMN1* and *SMN2*, i.e., SMA Carrier testing, is medically necessary for any of the following conditions:

- a. Couples seeking prenatal care; **OR**
- b. Couples who are planning a pregnancy; **OR**
- c. Persons with a family history of spinal muscle atrophy; **OR**
- d. Persons with a first degree relative identified as a spinal muscle atrophy carrier; **OR**
- e. Reproductive partners of persons with spinal muscle atrophy.

NOTE: Molecular testing reports of the affected individual and carrier testing of the related parent should be reviewed, if possible, before testing the patient. If the reports are not available, SMA Carrier testing should be recommended for the low-risk partner.

7. Tay-Sachs Disease:

Screening for Tay-Sachs disease is medical necessary for any of the following conditions:

- a. Persons with a family history consistent with Tay Sachs disease; **OR**
- b. Persons of Ashkenazi Jewish, French-Canadian or Cajun descent; **OR**
- c. Partner of a known carrier of Tay Sachs disease.

8. Evaluation of a fetus

Cytogenetic/chromosomal microarray testing (a.k.a., comparative genomic hybridization (CGH)) of amniotic fluid, placenta or products of conception for evaluation of a fetus is medically necessary for prenatal or postnatal testing in the evaluation of **ANY** of the following:

- a. In patients with a fetus with one or more structural abnormalities identified on ultrasound or magnetic resonance imaging (MRI) examination; **OR**
- b. In patients with third trimester intrauterine fetal demise, stillbirth, or infant born alive and died after birth from indeterminate causes; **OR**
- c. In patients with recurrent pregnancy loss and a clinically confirmed pregnancy loss in the first trimester, **OR**
- d. Evaluating Spitzoid melanocytic neoplasms that are histologically equivalent.

D. Indications Considered Experimental, Investigational or not Medically Necessary: *(Not all inclusive)*

- 1. Genetic disease whole gene panels, such as the Ashkenazi Jewish Panel including greater than the four diseases described in Sections C.
- 2. Requests for whole gene panel testing.
- 3. Routine preconception and prenatal screening for SMA in the general public.
- 4. Prenatal testing for autism spectrum disorder.
- 5. Cytogenic/chromosomal microarray testing (CGH) to screen for prenatal gene mutation in fetuses without structural abnormalities

HCPCS/CPT CODES:

81220	CFTR
81329	SMA Carrier Testing
81243	Fragile X
81260	Familial Dysautonomia
81200	Canavan Disease
81255	Tay-Sachs Disease
81271	Huntington Disease Mutation Analysis

References

American College of Medical Genetics (ACMG) Guideline, Carrier Screening in individuals of Ashkenazi Jewish descent; Vol.10; No.1; January 2008.

American College of Medical Genetics (ACMG) Guideline, Fragile X syndrome: Diagnostic and carrier testing; Vol. 7; No. 8; October 2005.

American College of Medical Genetics (ACMG) Guideline, Carrier Screening for Spinal Muscular Atrophy; Vol. 10; No.11; November 2008.

American College of Obstetricians and Gynecologists (ACOG), Committee on Genetics; Carrier Screening for Genetic Conditions; Number 691, March 2017.

American College of Obstetricians and Gynecologists (ACOG), Committee on Genetics; Carrier Screening in the Age of Genomic Medicine; Number 690, March 2017.

American College of Obstetricians and Gynecologists (ACOG), Committee Opinion No. 446: Array comparative genomic hybridization in prenatal diagnosis. *Obstet Gynecol.* 2009;114(5):1161-1163.

American College of Obstetricians and Gynecologists Committee on Genetics. Committee Opinion No. 581: The use of chromosomal microarray analysis in prenatal diagnosis. *Obstet Gynecol.* 2013;122(6):1374-1377.

Edwards JG, et al. Expanded carrier screening in reproductive medicine-points to consider. A Joint Statement of the American College of Medical Genetics and Genomics, American College of Obstetricians and Gynecologists, National Society of Genetic Counselors, Perinatal Quality Foundation, and Society for Maternal-Fetal Medicine. *Obstet Gynecol.* 2015;125(3):653-62.

Hayes, Inc. GTE Clinical Utility. Clinical utility of prenatal genetic testing for autism spectrum disorder. Publication date: September 28, 2018. Accessed: October 26, 2018

Hayes, Inc. GTE Indication.

- Genetic Testing for Fragile X-Associated Primary Ovarian Insufficiency (FXPOI). Publication date: March 9, 2017.
- Genetic testing for fragile X syndrome. Publication date: February 16, 2017. Annual review: March 21, 2018. Accessed: October 26, 2018

Scott S, Edelman L, Liu L, et.al. Experience with Carrier Screening and Prenatal Diagnosis for Sixteen Ashkenazi Jewish Genetic Diseases, *Hum Mutat.* November; 31(11); 1240-1250.

UpToDate. Spitzoid melanocytic neoplasms. Last update: August 10, 2017. Accessed: October 26, 2018.

Watson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, Mennuti M, Palomaki GE, Popovich BW, Pratt VM, Rohlfes EM, Strom CM, Richards CS, Witt DR, Grody WW. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. *Genetics in Medicine*; Vol. 6; No.5; September/October 2004.